Chinese Traditional and Herbal Drugs•2026•DOI: 10.7501/j.issn.0253-2670.2026.15.20261500
Phytochemical investigation of the branches and leaves of Aphanamixis polystachya (Meliaceae) yielded a previously undescribed labdane-type diterpenoid, designated as compound 1, together with known analogues. The structure of the new metabolite was established through comprehensive spectroscopic analysis, including HR-ESI-MS, 1D and 2D NMR (HSQC, HMBC, NOESY), and comparison with literature data. The absolute configuration was assigned by electronic circular dichroism (ECD) calculations. Compound 1 features a 1,4-dien-3-one moiety within a labdane skeleton, a structural motif rarely encountered in the Meliaceae family. All isolates were evaluated for their cytotoxic activities against a panel of human cancer cell lines (HepG2, A549, and MCF-7) using the MTT assay. Compound 1 exhibited moderate inhibitory effects with IC50 values ranging from 18.7 to 32.4 μM, while the positive control doxorubicin showed IC50 values of 0.8–2.1 μM. The discovery of this new diterpenoid expands the chemical diversity of A. polystachya and provides a potential scaffold for further anticancer drug development. However, the moderate potency and low yield (0.002% w/w) highlight the need for semisynthetic or biotechnological production strategies to enable preclinical evaluation.
Chinese Journal of Tissue Engineering Research•2026•DOI: 10.12307/2026.21608
BACKGROUND: At present, there are few longitudinal studies on postmenopausal cognitive impairment, and there is no systematic bibliometric analysis of its development context and hot trends. OBJECTIVE: To systematically integrate the related research on postmenopausal cognitive impairment with the help of bibliometric tools, identify the research trends and hot trends in this field, and promote interdisciplinary cooperation and clinical transformation. METHODS: The Web of Science Core Collection database was retrieved for literature related to postmenopausal cognitive impairment published from January 1, 2005 to March 24, 2025. Visualization analysis was conducted using software such as VOSviewer, the R package “Bibliometrix,” and CiteSpace. RESULTS AND CONCLUSION: A total of 1 452 articles were included, involving 71 countries, 1 830 institutions, 510 journals, and 6 909 authors. The annual publication volume showed a fluctuating upward trend. The United States dominated the field, with Stanford University, University of Pittsburgh, Harvard Medical School, and University of Illinois leading. Menopause-The Journal of the North American Menopause Society published the most articles (78), and JAMA-J Am Med Assoc had the highest co-citation count (3 791). Espeland, Mark A. ranked first with 55 publications, and Shumaker, Sally A. was the most co-cited author (859 times). High-frequency keyword “estrogen” (211 times) and burst keywords “plus progestin” (strength=15.77) and “estrogen replacement therapy” (strength=15.57) indicated that the long-term effects and safety of hormonal interventions remained the core research focus. Keyword clustering revealed four research directions. Future research could focus on constructing a “cross-life cycle-multidimensional” framework, which would help comprehensively understand the mechanisms of hormones on cognitive function and neuropsychiatric status at different life stages. The shift in hot topics from single issues (e.g., magnetic resonance imaging, hormones and cognition) to multiple health issues (psychological, tumor risk, cardiovascular, metabolic diseases, physical activity, etc.) and the non-hormonal turn in intervention strategies reflected the development trend of the discipline.